A Study of MabThera/Rituxan (Rituximab) in Patients With Relapsed Centroblastic Centrocytic Non-Hodgkin's Lymphoma

NCT01998893 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

38

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Hodgkin's Lymphoma

Interventions

DRUG: rituximab [MabThera/Rituxan]

Sponsor

Hoffmann-La Roche